Spotlight on Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Improvements in Lower Limb Function with Efgartigimod and Insights into Treatment Satisfaction of Conventional CIDP Therapies

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare immune-mediated disorder that affects sensory function and muscle strength. This article summarises selected data from poster and oral presentations on CIDP and the neonatal Fc receptor blocker, efgartigimod, at the European Academy of Neurology (EAN) Congress held in June 2025 in Helsinki, Finland. In the pivotal ADHERE trial, subcutaneous (SC) efgartigimod PH20 demonstrated clinical efficacy in the treatment of patients with CIDP, reducing relapse risk and improving disability scores. Data from post hoc analysis of the ADHERE trial exploring the effect of efgartigimod on lower limb function were presented by Simon Rinaldi from the University of Oxford, UK. Results showed that selective reduction of IgG with efgartigimod PH20 SC treatment improved lower limb function in patients with CIDP. Notably, over 20% of patients (33/144) who required support to walk at run-in baseline (the moment when patients had to stop their prior treatment) could walk outdoors independently after efgartigimod treatment in the open-label stage of ADHERE (Stage A), and over a third (9/25) who were previously wheelchair-bound were able to walk outdoors with support. Looking at CIDP through a broad lens, Sandra Paci from argenx in Ghent, Belgium, presented results from a real-world multinational survey that compared patients’ satisfaction with treatment across five European countries. Although some variability in treatment satisfaction was observed across the different countries, a clear association between disability level, fatigue, and satisfaction level was evident. The higher the level of disability and fatigue, the lower the probability of patients being satisfied with their treatment.